Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Irinotecan Pregnancy and Breastfeeding Warnings

Irinotecan is also known as: Camptosar

Medically reviewed on Oct 8, 2018

Irinotecan Pregnancy Warnings

Radioactivity related to radiolabeled irinotecan has been reported to have crossed the placenta in tests that have been conducted on rats. Embryotoxic effects appearing in rats and rabbits included increased post-implantation loss and decreased numbers of live fetuses. Teratogenic effects appearing in rats included a variety of external, visceral and skeletal abnormalities.

Irinotecan has been assigned to pregnancy category D by the FDA. It may cause fetal harm when administered to pregnant women. Animal studies have revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy.

See references

Irinotecan Breastfeeding Warnings

There are no data on the excretion of irinotecan into human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, mothers should discontinue nursing when receiving therapy with irinotecan.

Animal studies have reported the appearance of radioactivity in rat milk within 5 minutes of intravenous administration of radiolabeled irinotecan. Radioactive drug was concentrated up to 65-fold at 4 hours after administration relative to plasma concentrations.

See references

References for pregnancy information

  1. "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.

References for breastfeeding information

  1. "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.